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ABSTRACT 
Objective: To examine the combined effects of depressive symptoms and resting heart rate 
(RHR) on mortality.  
 
Methods: Data come from 5936 participants, aged 61 ±6 years, from the Whitehall II study. 
Depressive symptoms were assessed in 2002-2004 using the center-for-epidemiologic-studies-
depression-scale (score ≥16). RHR was measured at the same study phase via 
electrocardiogram. Participants were assigned to 1 of 6 risk-factor-groups based on depression 
status (yes/no) and RHR categories (<60, 60 - 80,
 
>80 bpm). Mean follow-up for mortality was 
5.6 years.  
 
Results: In mutually adjusted Cox regression models, depression (hazard ratio = 1.93 p<0.001) 
and RHR>80 bpm (hazard ratio = 1.67, p<0.001) were independent predictors of mortality. 
After adjustment for potential confounding and mediating variables, participants with both 
depression and high RHR had a 3.0-fold higher (p<0.001) risk of death compared to 
depression-free participants with RHR ranging from 60 to 80 bpm. This risk is particularly 
marked in participants with prevalent CHD.  
 
Conclusions: This study provides evidence that the coexistence of depressive symptoms and 
elevated RHR is associated with substantially increased risk of death compared to those 
without these two factors. This finding raises the possibility that treatments that
 
improve both 
depression and RHR might improve survival. 
 
Keywords: depression, resting heart rate and mortality 
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INTRODUCTION 
Depression is a major public health issue worldwide 
1
. Projections of the Global Burden 
of Disease by the WHO suggest that depression will account for 10% of the total disease burden 
in high-income countries by 2030 
2
. There is fairly consistent evidence that depression is 
independently associated with increased risk of mortality 
3-7
. For example, a recent meta-analysis 
of 25 community studies on a total of 106,628 individuals found a 1.8-fold increased risk for all-
cause mortality in depressive compared to non-depressive subjects 
8
.  
Resting heart rate (RHR), an indicator of the autonomic nervous system activity, has 
also been found to be an independent predictor of mortality 
9-11
. In a recent study of working 
men without clinically detectable cardiovascular diseases (CVD) at baseline followed up for 23 
years, the risk for sudden and non-sudden death from acute myocardial infarction and all-cause 
mortality increased in a dose-response manner with increasing RHR, after adjustment for 
biobehavioral risk factors 
12
. Another recent study involving a large sample of men and women 
found elevated RHR to be a long-term predictor for mortality independent of other risk factors 
in patients with suspected or proven coronary artery disease 
13
.  
Despite the large amount of evidence showing depression and RHR to be predictors of 
mortality, previous studies have not examined the combined impact of depression and RHR. 
However, in many individuals depression and elevated RHR are co-morbid 
14-16
 and it is 
possible that they exert a combined effect on mortality. Indeed, several studies found clinically 
depressed psychiatric patients and CHD patients with depression, as compared with their non-
depressed counterparts, to have elevated levels of plasma catecholamines and other markers of 
altered autonomic nervous system (ANS) activity, including elevated heart rate, low heart rate 
variability, exaggerated heart rate responses to physical stressors 
14-20
. All these indicators of 
altered ANS function have been found to be associated with increased risks of mortality and 
cardiac morbidity in patients with CHD
14
. 
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We are aware of no published study that examined mortality risk as a function of both 
depression status and RHR level. To address this issue, the present study examines the 
combined effect of depressive symptoms and RHR on mortality in a large cohort of middle-
aged British adults. 
 
MATERIAL & METHODS 
Data are drawn from the Whitehall II study, established in 1985 as a longitudinal cohort 
study to examine the socioeconomic gradient in health and disease among 10,308 civil servants 
(6,895 men and 3,413 women). All civil servants aged 35-55 years in 20 London based 
departments were invited to participate by letter, and 73% agreed. Baseline screening (Phase 1) 
took place during 1985-1988, and involved a clinical examination and a self-administered 
questionnaire. Subsequent phases of data collection have alternated between postal 
questionnaire alone [Phases 2 (1989-1990), 4 (1995-1996), 6 (2001) and 8 (2006)] and postal 
questionnaire accompanied by a clinical examination [Phases 3 (1991-1993), 5 (1997-1999) 
and 7 (2002-2004)]. The University College London ethics committee approved the study. 
Measures 
Depressive symptoms 
Depressive symptoms were assessed using the Center for Epidemiologic Studies
 
Depression Scale (CES-D, Cronbach‟s alpha = 0.83) at phase 7 of the Whitehall II study 
(2002-2004). The CES-D, a widely used and validated
 
instrument, is a 20-item self-report 
questionnaire designed
 
to measure depressive symptomatology in community studies 
21
. A 
score ≥16 from a total possible score of 60 has been used extensively to distinguish depressed 
from nondepressed subjects 
21
.   
Resting Heart Rate 
RHR was measured at the phase 7 screening clinic via electrocardiogram (ECG) on 
participants in the supine position following a standard protocol. The following classification 
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was used to categorize RHR: RHR<60, 60≤RHR≥80, and RHR>80 beats/minute (bpm), based 
on current guidelines that have defined adequate rate control as a ventricular response between 
60 and 80 bpm at rest 
22
.  
Vital status 
Mortality follow-up was available through the British National Health Services Central 
Registry until 30
th
 April 2009. Death certificates were coded using the 10
th
 revision of the 
International Classification of Disease (ICD). All-cause mortality was the main outcome in our 
analysis. 
Covariates 
Sociodemographic measures  
Sociodemographic measures included age, sex, ethnicity, and socioeconomic position 
(SEP) assessed by British civil service grade of employment taken from the phase 7 
questionnaire. 
Biobehavioral risk factors  
Behavioral risk factors were assessed using response to the phase 7 questionnaire and 
were categorized as follows: smoking status (never, ex, and current), physical activity (≥1.5 or 
<1.5 hours of moderate or vigorous exercise/week), alcohol consumption in the previous
 
week 
was categorized as abstention, moderate (1–14 units for women/1–21 units for men), and high 
consumption (14+ units
 
for women/21+ units for men). A unit is 10 ml or 8 grams of pure 
alcohol. The following biological CVD risk factors were measured at phase 7 clinical 
examination: hypertension (systolic blood pressure >140 mm/Hg or diastolic blood pressure 
>90 mm/Hg or antihypertensive medications), high total blood cholesterol (≥ 6.2 mmol/l), 
body mass index (BMI) (<20, 20-24.9, 25-29.9, or ≥30 kg/m2) and diabetes, assessed via 
glucose tolerance test at the medical screening or self-report of doctor diagnosis.  
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Medications 
Data on antidepressant medications was drawn from the phase 7 questionnaire where 
participants were asked whether in the last 14 days they had taken antidepressants drugs 
prescribed by a doctor (yes/no). CVD medications at phase 7 were also drawn from questions 
on whether in the last 14 days the participant had taken CVD drugs, including diuretics, beta 
blockers, ACE inhibitors, calcium channel blockers, nitrates, antiplatelets prescribed by a 
doctor (yes/no). The same question was used to assess whether participants had taken lipid-
lowering medications. 
Prevalent Coronary heart disease (CHD)  
CHD status at phase 7 was defined as non-fatal myocardial infarction (MI ) or „definite‟ 
angina and was based on clinical examinations at phases 1, 3, 5, and 7 and records obtained 
from general practitioners and hospitals. Potential non-fatal myocardial infarction was 
ascertained by
 
questionnaire items on chest pain (the World Health Organisation Rose 
questionnaire 
23) and the physician‟s diagnosis of heart attack. Confirmation of myocardial 
infarction according to MONICA
24
 criteria (Multinational Monitoring of Trends and 
Determinants
 
in Cardiovascular Disease) was based on electrocardiograms,
 
markers of 
myocardial necrosis, and chest pain history from
 
medical records. Angina was assessed based 
on participant‟s reports of symptoms with corroboration in medical records or abnormalities on 
a resting electrocardiogram, an exercise electrocardiogram,
 
or a coronary angiogram.  
 
Statistical analysis 
Differences in depression status and RHR categories as a function of the sample 
characteristics were assessed using a chi-square test. The associations of depression and RHR 
with mortality were examined separately using Cox regressions in 4 serially adjusted models. 
A resting heart rate between 60-80 bpm was used as the reference category so that the hazard 
ratios (HRs) of lower RHR (< 60 bpm ) and higher RHR (above 80 bpm) were estimated .In 
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model 1, HRs were adjusted for the following socio-demographic characteristics: sex, age, 
ethnicity and SEP. Model 2 additionally adjusted the hazard of mortality for smoking, BMI, 
alcohol consumption, physical activity, hypertension, total blood cholesterol and diabetes. 
Model 3 was model 1 additionally adjusted for CVD medication (diuretics, beta blockers, ACE 
inhibitors, calcium channel blockers, nitrates, antiplatelets), antidepressant medication, lipid 
lowering medication, and history of CHD. Model 4 included all aforementioned variables, 
depression and RHR categories, in order to estimate their independent effect on mortality. 
To examine the combined effect of depression and RHR on mortality, we divided the 
study sample into six groups based on the cross classification of depression status (depression, 
CES-D ≥16 vs. no depression, CES-D < 16) and RHR categories (<60, 60 - 80, >80 bpm) with 
non-depressive participants with RHR between 60 and 80 bpm taken as the reference group.  
Cox regressions models were used to calculate multivariable-adjusted risk of death for 
each group compared with the reference group using the adjustment specified in models 1 and 
2 above. The proportional hazards assumption was checked graphically by plotting the log of 
the negative log of the survival function. These curves were essentially parallel, suggesting 
therefore that the proportional hazard was not violated. 
We also examined the additive interaction between depressive symptoms and elevated 
RHR as defined by Rothman 
25
 by calculating the relative excess risk due to interaction (RERI) 
26
 using the methods
 
outlined by Andersson et al. 
27
. For example, a RERI of 4.0 would mean 
that the relative risk of death from all-causes in depressive participants with elevated RHR is 
increased by 4.0 compared to the relative risk that one would expect if there were no 
interaction between these two factors. In the absence of an interaction between
 
depressive 
symptoms and RHR, the RERI will be 0.
  
Probability
 
values and 95% CIs for the RERI were 
computed by the delta method 
28
. 
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RESULTS 
A total of 5936 participants were included in the analyses. Of them, 170 died during the 
mean follow-up period of 5.6 years (SD 0.7, range 0.03-6.6). The mean age of the participants 
at phase 7, the start of the follow-up for our analysis, was 61 years (SD 6.0). The prevalence of 
depression (CES-D ≥16) was 14.9%. 24% of participants had RHR<60 bpm, 61 % were in the 
normal range with RHR between 60 and 80 bpm and 15% had RHR >80 bpm. Compared to 
participants included in this study, those who did not respond to the CES-D questionnaire or 
did not have data on RHR were more likely to be: women (39.8% vs. 29.1%, p<0.001), non-
white (15.2% vs. 8.4%, p <0.001), older (19.5% vs. 9.3%, p<0.001), and from lower SEP 
(34.1% vs. 15.9%, p<0.001). 
Table 1 shows the sample characteristics as a function of depression status and RHR 
categories at phase 7. Participants with depressive symptoms were more likely to be female, 
younger, from lower SEP, non-white, on medication (antidepressants, nitrates and 
antiplatelets), current smokers, less physically active, and to have lower BMI and higher 
prevalence of diabetes and CHD (all p ≤ 0.04). Men were more likely to have low RHR (<60 
bpm, p<0.001). Participants with higher RHR (>80 bpm) were more likely to be from lower 
SEP, less physically active, hypertensive, obese, diabetic, on CVD medication (beta blockers, 
nitrates, antiplatelets) and lipid-lowering medication, and to have depressive symptoms (all p 
≤0.032). 
Table 2 presents estimates from Cox regression models for the associations between 
depressive symptoms, RHR and mortality. In model 1 adjusted for socio-demographic 
characteristics, depressive participants (CES-D ≥ 16) were at increased risk of death (HR = 
2.46, 95% CI 1.74-3.48), when compared to nondepressive participants (CES-D < 16). Using 
the same adjustments, but with RHR as the predictor, participants with RHR >80 bpm were at 
increased risk of death from any cause (HR = 1.70, 95% CI 1.18-2.44) compared to those with 
RHR between 60 and 80 bpm. In model 2 adjusted for CVD biobehavioral risk, the magnitude 
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of the associations was reduced, but participants with depressive symptoms remained at greater 
risk of mortality. Participants with RHR > 80 bpm were also at greater risk of mortality. In 
model 3, adjustments for CVD, antidepressant and lipids lowering medication and prevalent 
CHD did not alter the associations observed in model 1. Inclusion of all of these variables and 
both depression and RHR in model 4 did not substantially affect these associations; both 
depressive symptoms (HR=1.93, 95% CI 1.35-2.76) and high RHR (HR=1.67, 95% CI 1.14-
2.45) remained independently associated with an increased risk of mortality.  
Table 3 shows the associations of combinations of depression status and RHR 
categories with mortality as the outcome. Model 1, adjusted for sociodemographic 
characteristics, shows that compared with the reference group (participants without depression 
and with RHR between 60 and 80 bpm), the hazard of death was higher for depressive 
participants with RHR between 60 and 80 bpm (2.71, 95% CI 1.73-4.23), for those without 
depression but with RHR >80 bpm (1.80, 95% CI 1.17-2.76), and for those with both 
depression and RHR >80 bpm (3.85, 95% CI 2.03-7.31). After further multivariate adjustment 
for biobehavioral risk factors in model 2, the magnitude of the associations was reduced, but 
the associations persisted. In model 3, adjustment for CVD, antidepressant and lipid lowering 
medications, and prevalent CHD did not substantially alter the associations observed in model 
1. Finally, after inclusion of all these variables in model 4, the hazard for death was 2.1-fold 
(p<0.001) higher for participants with depression but with RHR between 60 and 80 bpm, 1.8-
fold (p<0.001) higher for those without depression but with RHR >80 bpm, and 3-fold 
(p<0.001) higher for those with both depression and RHR >80 bpm. The RERI between 
depressive symptoms and elevated RHR was 0.20 (95% CI, -2.17-2.5). 
Sensitivity analyses 
In order to assess the robustness of the present findings, we repeated the analyses 
excluding participants with a personal history of CHD. The number of deaths was reduced by 
22% (n deaths=133). In fully mutually-adjusted model, depressive symptoms (HR=1.82, 
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p=0.005) and elevated RHR (>80 bpm, HR= 1.63, p=0.03) remained independent predictors of 
death. The corresponding fully adjusted risk of death was 2.5-fold (p=0.04) higher for 
participants with both depressive symptoms and RHR > 80 bpm when compared to those 
without depressive symptoms and with RHR between 60 and 80 bpm. The corresponding 
RERI was -0.60 (95% CI, -2.90-1.71). Similar patterns of association were observed when the 
analyses were restricted to participants with prevalent CHD (n deaths = 37). The corresponding 
fully mutually adjusted HRs were 2.97 (p=0.006) for depressive symptoms and 2.00 (p=0.17) 
for those with RHR > 80 bpm. Finally, participants with both depressive symptoms and RHR 
>80 bpm had a 7.5-fold (p=0.005) higher risk of death relative to those without depressive 
symptoms and with RHR between 60 and 80 bpm. The corresponding RERI was 2.39 (95% CI, 
-4.13-8.90). 
In addition, we repeated the analysis in subgroups of beta blockers users and non-users. 
In fully mutually-adjusted model, depressive symptoms (HR=2.14, p<0.001) and elevated 
RHR (>80 bpm, HR= 1.57, p=0.025) remained independent predictors of death (n=142) among 
non beta blockers users. The corresponding fully adjusted risk of death was 3.22-fold 
(p≤0.001) higher for participants with both depressive symptoms and RHR > 80 bpm when 
compared to those without depressive symptoms and with RHR between 60 and 80 bpm. 
Among beta blockers users (n deaths= 28) the corresponding HRs were 0.99 (p=0.99) for 
depressive symptoms and 2.48 (p=0.26) for elevated RHR. Only two beta blocker users had 
depressive symptoms and RHR > 80 bpm thus preventing further analysis of this group. 
Although the risk of death seems to be lower among beta blocker users, the small number of 
deaths among this group precludes any definite conclusions regarding these observations. 
 
DISCUSSION 
In this study we sought to examine the combined effect of depressive symptoms and 
RHR on mortality in a large cohort of British adults. We found that depressive symptoms and 
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elevated RHR were independent predictors for death from all-causes over 5 years of follow up. 
Concurrently, the study also shows that the coexistence of depression and higher RHR is 
associated with substantially elevated risk of death from all-causes beyond the effect of having 
either depression or elevated RHR alone. For instance, after adjustment for relevant 
biobehavioral risk factors, participants with both depression and RHR >80 bpm were at a 3-
fold higher risk of death when compared to those without depression and with RHR ranging 
from 60 to 80 bpm. This risk is particularly marked in participants with prevalent CHD where 
there was some evidence of an additive interaction between depressive symptoms and elevated 
RHR. 
Findings in context of the literature and possible mechanisms 
To our knowledge, this is the first prospective cohort study to compare the effects of 
depressive symptoms on mortality in individuals as a function of their RHR. Our findings are 
based on a large well-characterized cohort with depression symptomatology assessed by a 
validated scale and biological risk factors assessed by clinical examination. We found that both 
depression and RHR were strong predictors of death independently of biobehavioral risk 
factors and of each other. This is consistent with previous studies 
3-5, 9-11
 , even though these 
studies usually considered depression and RHR as individual predictors and rarely showed 
mutually adjusted analyses. In comparisons across the six exposure categories, we also found 
that participants with co-existing depression and elevated RHR (>80 bpm) were more likely to 
die than were participants in any of the other five combinations. Moreover, participants with 
depression but with RHR ranging from 60 to 80 bpm were at increased risk of mortality 
compared to those without depression and RHR > 80 bpm, RHR considered to be elevated. 
These results suggest that the effect of depression on mortality is strong and it is perhaps a 
stronger predictor of death than RHR in this cohort of middle-aged men and women.  
Although this study did not aim to examine the mechanisms that could explain the 
current observations, several hypotheses seem possible. The finding showing depression to be 
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associated with increased risk of all-cause mortality suggests that depression may act as an 
exacerbating factor in the progression of other medical illnesses 
29
. Although depression is 
thought to be implicated in the development of certain physical illnesses such as CVD 
30
, 
secondary depression, where a diagnosed or undiagnosed medical illness precedes depression, 
is also possible. In this case, depression may appear to be a marker of the severity of physical 
illnesses 
31, 32
. The coexistence of depression with other medical illnesses may impair recovery 
and increase the risk of mortality by impeding treatment seeking, adherence to 
pharmacological and behavioral regimens, and adoption of healthy life-styles 
33
. 
The association between RHR and mortality is plausible because RHR is a marker of both 
autonomic nervous system and cardiorespiratory fitness, both of which, when impaired, are 
associated with the risk of death 
34, 35
. Although an elevated RHR might be the reflection of 
poor underlying health status 
10
, it is primarily an indicator of cardiorespiratory fitness which is 
related to physical fitness 
34
. Indeed, exercise capacity is a powerful predictor of mortality 
34
 
and RHR is lower in individuals who undertake vigorous physical activity 
36
. Depression has 
been shown to be associated with decreased cardiorespiratory fitness 
37
 which may be the 
consequence of a lower engagement of individuals in physical activity. Data from the 
Established Populations Epidemiologic Studies of the Elderly cohort provide some evidence 
that physical activity is one of the mechanisms underlying the link between depression and 
physical decline, as those who were depressed undertook less walking, gardening, and vigorous 
physical activities 
33
. This may explain why depression has been found to be associated with 
high RHR, although depression itself could also affect physical fitness and subsequently RHR 
levels by directly modulating central nervous system pathways 
14, 38
. Furthermore, despite the 
independent effects observed in this study, high RHR and depression may be associated due to 
partially shared biological processes. Increased RHR in depressive participants could reflect 
deficits in cardiac vagal control. It is known that cardiac vagal activity when unaltered 
decreases cardiac activity by reducing RHR and contractility.
39
 However, there is also some 
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evidence showing an increased RHR in the absence of reduced vagal tone in depressed patients 
40
. Recent studies have shown depression to be associated with low heart rate variability 
41, 42
, 
an index of reduced cardiac vagal activity, which has been found to be a risk factor for all 
cause and cardiac mortality 
43, 44
.  
 Considering the plausibility of the influence of depression on RHR via behavioral and 
pathophysiological mechanisms and their independent link with mortality, it is highly possible 
that they exert a combined effect on mortality risk. However, the underlying mechanisms, 
including the vagal mechanism, behind this association need to be examined in future studies.  
Study limitations 
In interpreting the present results, it is important to note some limitations. First, this 
cohort of civil servants did not include blue collar workers, unemployed or younger adults; 
thus it is not representative of the general population of working age, which may limit the 
generalisability of our findings. Second, we assessed depressive symptoms rather than clinical 
depression. However, it has been suggested that significant depressive symptomatology could 
be a risk factor for clinical
 
depression 
21
. Finally, we did not have the power to examine cause 
specific mortality but the results for all cause mortality are robust. The lack of power may also 
explain why the confidence interval around the RERI estimating the interaction between 
depressive symptoms and elevated RHR was large among participants with CHD, but did not 
reach statistical significance. Although this finding is consistent with the idea that depression 
and RHR are general rather that specific risk factors of any disease, 
10, 45
 further studies should 
examine whether depression and elevated RHR exert a combined effect on CVD, cancer, and 
non CVD mortality.  
Conclusions and implications of this finding 
Despite these potential limitations, depression is increasingly recognized to have an 
important predictive and prognostic value and this study provides additional evidence that the 
coexistence of depressive symptoms and elevated RHR is associated with substantially 
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increased risk of death. Our findings raise the possibility that treatments that
 
improve both 
depression and RHR might improve survival.  
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Table 1. Sample characteristics as a function of Depression and Resting Heart Rate at phase 7 
  Depressive symptoms  
(CES-D score ≥16) 
 
Resting Heart Rate categories  
Variables  
N total 
 
N (%) 
 
p value 
 
< 60 bpm 
N (%) 
 
60-80 bpm 
N (%) 
 
>80 bpm 
N (%) 
 
p value 
Sex                                  < 0.001    < 0.001 
       Male  4268 559 (13.1)  1124 (79.2) 2498 (68.8) 646 (73.0)  
       Female  1668 326 (19.5)  296 (20.8) 1133 (31.2) 239 (27.0)  
Age in years                                     < 0.001    0.703 
       < 54  1110 212 (19.1)  250 (17.6) 721 (19.9) 139 (15.7)  
       54-59  1822 272 (14.9)  421 (29.6) 1139 (31.4) 262 (29.6)  
       60-64  1259 163 (12.9)  321 (22.6) 746 (20.5) 192 (21.7)  
       65-69  1196 163 (13.6)  275 (19.4) 717 (19.7) 204 (23.1)  
       70-74 549 75 (13.7)  153 (10.8) 308 (8.5) 88 (9.9)  
SEP                          < 0.001    < 0.001 
       High  2040 201 (9.9)  546 (38.5) 1221 (33.6) 273 (30.8)  
       Middle  3032 469 (15.5)  717 (50.5) 1831 (50.4) 484 (54.7)  
       Low  864 215 (24.9)  157 (11.1) 579 (15.9) 128 (14.5)  
Ethnicity   < 0.001    0.543 
       White 5485 743 (13.5)  1320 (93.0) 3347 (92.2) 818 (92.4)  
       Other 451 142 (31.5)  100 (7.0) 284 (7.8) 67 (7.6)  
Smoking status                                       < 0.001    0.479 
       Never smoker  2678 377 (14.1)  639 (45.0) 1637 (45.1) 402 (45.4)  
       Ex smoker  2282 297 (13.0)  556 (39.2) 1364 (37.6) 362 (40.9)  
       Current smoker  680 145 (21.3)  157 (11.1) 437 (12.0) 86 (9.7)  
       Missing 296 66 (22.3)  68 (4.8) 193 (5.3) 35 (4.0)  
Alcohol consumption                                 0.514    0.755 
       Abstainers 973 220 (22.9)  206 (14.5) 604 (16.6) 163 (18.4)  
       Moderate 3725 484 (13.0)  9439 (66.1) 2286 (63.0) 500 (56.5)  
       High  1158 153 (13.2)  254 (17.9) 691 (19) 213 (24.1)  
       Missing 80 28 (35.0)  21 (1.5) 50 (1.5) 9 (1.0)  
Exercise                                             < 0.001    < 0.001 
       ≥ 1.5 h / week        5152 699 (13.6)  1277 (89.9) 3134 (86.3) 741 (83.7)  
       < 1.5 h / week        784 186 (23.7)  143 (10.1) 497 (13.7) 144 (16.3)  
Hypertension   0.315    0.032 
       No  3585 521 (14.5)  811 (57.1) 2336 (64.3) 438 (49.5)  
       Yes  2351 364 (15.5)  609 (42.9) 1295 (35.7) 447 (50.5)  
BMI (kg/m²)                                     0.002    < 0.001 
       < 20  179 38 (21.2)  53 (3.7) 108 (3.0) 18 (2.0)  
       20-24.9  2028 263 (13.0)  570 (40.1) 1242 (34.2) 216 (24.4)  
       25-29.9  2606 365 (14.0)  588 (41.4) 1627 (44.8) 391 (44.2)  
       ≥ 30  1099 214 (19.5)  206 (14.5) 638 (17.6) 255 (28.8)  
       Missing 24 5 (20.8)  3 (0.2) 16 (0.4) 5 (0.6)  
Diabetes   < 0.001    < 0.001 
       No 5656 816 (14.4)  1371 (96.5) 3470 (95.5) 815 (92.1)  
       Yes  281 69 (24.6)  49 (3.5) 162 (4.5) 70 (7.9)  
High blood cholesterol   0.266    < 0.174 
       No 3940 599 (15.2)  991 (69.2) 2401 (66.1) 548 (61.9)  
       Yes 1886 263 (13.9)  396 (27.9) 1174 (32.2) 316 (35.7)  
       Missing 110 23 (20.9)  33 (2.3) 56 (1.5) 21 (2.4)  
Antidepressant drugs   < 0.001    0.842 
       No  5728 786 (13.7)  1366 (96.2) 3514 (96.8) 848 (95.8)  
       Yes  208 99 (47.9)  54 (3.8) 117 (3.2) 37 (4.2)  
CVD medications (Yes)        
       Diuretics 494 76 (15.4) 0.757 135 (9.5) 277 (7.6) 82 (9.3) 0.518 
       Beta Blockers 584 91 (15.6) 0.631 345 (24.3) 223 (6.1) 16 (1.8) < 0.001 
       ACE Inhibitors 649 110 (16.9) 0.122 164 (11.5) 356 (9.8) 129 (14.6) 0.113 
       Calcium Channel Blockers 420 67 (16.0) 0.533 118 (8.3) 228 (6.3) 74 (8.4) 0.614 
       Nitrates 62 18 (29.0) 0.002 27 (1.9) 33 (0.9) 2 (0.2) < 0.001 
       Antiplatelets 584 104 (17.8) 0.038 199 (14.0) 310 (8.5) 75 (8.5) < 0.001 
Lipid lowering medications   0.242    0.001 
       No 5247 772 (14.7)  1207 (85.0) 3253 (89.6) 787 (88.9)  
       Yes 689 113 (16.4)  213 (15.0) 378 (10.4) 98 (11.1)  
History of CHD   0.001    < 0.001 
       No 5385 777 (14.4)  1229 (86.5) 3348 (92.2) 808 (91.3)  
       Yes 551 108 (19.7)  191 (13.5) 283 (7.8) 77 (8.7)  
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Depressive symptoms   
(CES-D ≥16) 
      0.007 
       No  5051   1239 (87.3) 3074 (84.7) 738 (83.4)  
       Yes  885   181 (12.7) 557 (15.3) 147 (16.6)  
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Table 2. Associations between Depression, Resting Heart Rate and Mortality 
 
  Mortality risk 
 
Predictors 
n events/n 
participants 
 
HR 
 
95% CI 
 Model 1 
Depressive symptoms 170/5936   
  Score ≤ 15 123/5051 1 reference 
  Score ≥16 47/885 2.46 (1.74-3.48)‡ 
 
Resting Heart Rate  170/5936   
  < 60 bpm 33/1420 0.85 (0.57-1.26) 
  60 bpm ≥ HR ≤ 80 bpm 95/3631 1 reference 
   > 80 bpm 42/885 1.70 (1.18-2.44)† 
 Model 2 
Depressive symptoms    
  Score ≤ 15  1 reference 
  Score ≥16  1.98 (1.39-2.82)‡ 
 
Resting Heart Rate     
  < 60 bpm  0.85 (0.57-1.27) 
  60 bpm ≥ HR ≤ 80 bpm  1 reference 
   > 80 bpm  1.54 (1.06-2.23)* 
 Model 3 
Depressive symptoms    
  Score ≤ 15  1 reference 
  Score ≥16  2.42 (1.70-3.45)‡ 
 
Resting Heart Rate     
  < 60 bpm  0.69 (0.45-1.06) 
  60 bpm ≥ HR ≤ 80 bpm  1 reference 
   > 80 bpm  1.74 (1.21-2.52)† 
 Model 4 
Depressive symptoms    
  Score ≤ 15  1 reference 
  Score ≥16  1.93 (1.35-2.76)‡ 
 
Resting Heart Rate     
  < 60 bpm  0.75 (0.49-1.15) 
  60 bpm ≥ HR ≤ 80 bpm  1 reference 
   > 80 bpm  1.67 (1.14-2.45)† 
* p<0.05, †p<0.01, ‡p<0.001 
Model 1: adjusted for sex, age, ethnicity and SEP 
Model 2: model 1 additionally adjusted for BMI, alcohol consumption, smoking status, exercise, hypertension, 
antihypertensive drugs,    total blood cholesterol, and diabetes. 
Model 3: model 1 additionally adjusted for: CVD medication (diuretics, beta blockers, ACE inhibitors, calcium channel 
blockers, nitrates, antiplatelets), antidepressant medication, lipid lowering medication and history of CHD 
Model 4: adjusted for all aforementioned variables and depression for the association between resting heart rate and 
mortality or resting heart rate for the association between depression and mortality. 
** n events / n total is the same in all models. 
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       Table 3. Hazard ratios for mortality as a function of combinations of depression and resting heart rate. 
 
 RHR < 60 bpm 60≥ RHR ≤ 80 bpm RHR > 80 bpm 
Model 1 
Depressive symptoms    
 
No 
n events/n total 26/1239 66/3074 29/738 
HR (95% CI) 0.92 (0.58-1.45) 1 (reference) 1.80 (1.17-2.76)† 
 
 
Yes 
n events/n total 7/181 29/557 11/147 
HR (95% CI) 1.88 (0.86-4.13) 2.71 (1.73-4.23)‡ 3.85 (2.03-7.31)‡ 
 
Model 2 
Depressive symptoms    
 
No 
 
    
HR (95% CI) 0.92 (0.58-1.46) 1 (reference) 1.66 (1.08-2.56)* 
 
Yes 
    
HR (95% CI) 1.55 (0.70-3.42) 2.21 (1.41-3.49)‡ 2.81 (1.46-5.56)† 
 
Model 3 
Depressive symptoms    
 
No 
 
    
HR (95% CI) 0.75 (0.46-1.21) 1 (reference) 1.84 (1.20-2.83)† 
 
Yes 
    
HR (95% CI) 1.67 (0.76-3.70) 2.55 (1.62-4.04)‡ 3.67 (1.92-7.02)‡ 
 
Model 4 
Depressive symptoms    
 
No 
 
    
HR (95% CI) 0.79 (0.48-1.28) 1 (reference) 1.77 (1.14-2.75)† 
 
Yes 
    
HR (95% CI) 1.40 (0.63-3.13) 2.10 (1.32-3.32)‡ 2.99 (1.53-5.81)‡ 
     
* p<0.05, †p<0.01, ‡p<0.001 
Model 1: hazard ratios (HR) adjusted for sex, age, ethnicity and SEP 
Model 2: model 1 additionally adjusted for BMI, alcohol consumption, smoking status, exercise, hypertension, 
antihypertensive drugs, total blood cholesterol, and diabetes. 
Model 3: model 1 additionally adjusted for:  CVD medication (diuretics, beta blockers, ACE inhibitors, calcium channel 
blockers, nitrates, antiplatelets), antidepressant medication, lipid lowering medication and history of CHD 
Model 4: HRs adjusted for all aforementioned variables  
** n events / n total is the same in all models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
21 
 
 
